20:18 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Apricus get CRL for ED candidate Vitaros

Apricus Biosciences Inc. (NASDAQ:APRI) said it received a complete response letter to a resubmitted NDA for Vitaros alprostadil to treat erectile dysfunction. The company said FDA cited CMC and safety concerns specific to the 2.5%...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
21:29 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

FDA accepts resubmitted NDA for Apricus' Vitaros

FDA accepted for review a resubmitted NDA for Vitaros alprostadil from Apricus Biosciences Inc. (NASDAQ:APRI) to treat erectile dysfunction. The PDUFA date is Feb. 17, 2018. Vitaros is a topical prostaglandin E1 (PGE1) cream formulated with...
18:50 , Mar 17, 2017 |  BC Week In Review  |  Company News

Apricus, Ferring deal

Apricus sold to Ferring remaining ex-U.S. rights and assets related to erectile dysfunction drug Vitaros alprostadil for $11.5 million upfront, plus up to $700,000 for product inventory and up to $500,000 for transition assistance. Ferring...
22:43 , Jan 20, 2017 |  BC Week In Review  |  Clinical News

Vitaros regulatory update

Apricus said Mexico approved Vitaros alprostadil to treat erectile dysfunction (ED). Ferring Pharmaceuticals A/S (Saint-Prex, Switzerland), which has exclusive rights to market Vitaros to treat ED in Latin America, plans to launch Vitaros next quarter...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year. This year...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Allergan, Apricus Biosciences deal

Allergan granted Apricus exclusive rights to develop and commercialize Vitaros alprostadil in the U.S. Allergan will receive $1 million up front and is eligible to receive a $1.5 million regulatory milestone payment, plus double-digit...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

RayVa alprostadil: Phase IIa data

Top-line data from a double-blind, placebo-controlled, crossover, U.S. Phase IIa trial in about 35 patients with Raynaud’s disease secondary to scleroderma showed that 300, 1,000 and 3,000 ug topical RayVa led to no significant safety...